What's in Sun Pharmaceutical Industries, Inc.'s pipeline?

Sun Pharmaceutical Industries, Inc. has 49 drugs in our index: 3 marketed, 0 filed, 7 in Phase 3, 9 in Phase 2, 30 in Phase 1.

Which companies overlap with Sun Pharmaceutical Industries, Inc.'s portfolio?

Top competitors by shared drug class: Pfizer, Stiefel, a GSK Company, GlaxoSmithKline, Avalo Therapeutics, Inc., AJU Pharm Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sun-pharmaceutical-industries-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Sun Pharmaceutical Industries, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sun Pharmaceutical Industries, Inc. pipeline: 3 marketed, 0 filed, 7 Phase 3, 9 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 7 Phase 3 9 Phase 2 30 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Placebo topical cream	Placebo topical cream	marketed
Desoximetasone Spray 0.25%	Desoximetasone Spray 0.25%	marketed	Topical corticosteroid	Glucocorticoid receptor	Dermatology
Lotrimin Ultra®	Lotrimin Ultra®	marketed	Allylamine antifungal	Squalene epoxidase	Dermatology / Infectious Disease
Ovide (malathion) lotion 0.05%	Ovide (malathion) lotion 0.05%	phase 3	insecticide		Dermatology
DSXS topical	DSXS topical	phase 3			Dermatology
Naftifine Hydrochloride Cream 2%	Naftifine Hydrochloride Cream 2%	phase 3	Allylamine antifungal	Squalene epoxidase	Dermatology / Infectious Disease
Permethrin 1% rinse	Permethrin 1% rinse	phase 3	pyrethroid		Dermatology
Onexton™ Gel	Onexton™ Gel	phase 3	Topical antibiotic combination	Bacterial ribosome (clindamycin); oxidative mechanism (benzoyl peroxide)	Dermatology
Malathion gel 0.5%	Malathion gel 0.5%	phase 3	Organophosphate insecticide	Acetylcholinesterase	Dermatology / Parasitology
DSXS	DSXS	phase 3	SGLT2 inhibitor	SGLT2	Diabetes

Therapeutic area mix

Dermatology · 7
Dermatology / Infectious Disease · 2
Dermatology / Parasitology · 1
Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 4 shared drug classes
Stiefel, a GSK Company · 3 shared drug classes
GlaxoSmithKline · 3 shared drug classes
Avalo Therapeutics, Inc. · 2 shared drug classes
AJU Pharm Co., Ltd. · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Allergan · 2 shared drug classes
Ache Laboratorios Farmaceuticos S.A. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Sun Pharmaceutical Industries, Inc.:

Cite this brief

Drug Landscape (2026). Sun Pharmaceutical Industries, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sun-pharmaceutical-industries-inc. Accessed 2026-05-17.